Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils.

Melanoma Res

aDepartment of Dermatology bDepartment of Pathology, Institute for Clinical Pathology and Medical Research, Westmead Hospital cDepartment of Dermatology, Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.

Published: December 2017

The introduction of anti-programmed cell death-1 (anti-PD1) monoclonal antibodies has revolutionized the treatment of various advanced malignancies. Despite its efficacy, anti-PD1 therapy is accompanied by a variety of cutaneous adverse events. A 79-year-old man developed erythematous scaly plaques and pustules of the forehead, legs and arms after four cycles of nivolumab infusions every 2 weeks. Histology showed intracorneal pustules with dermal neutrophils and eosinophils. He was treated successfully with topical corticosteroids without discontinuation of nivolumab. We report subcorneal pustular eruption as a novel cutaneous adverse event in patients on anti-PD1 therapy. Other neutrophilic eruptions (psoriasis, Sweet's syndrome, acute generalized pustulosis) have been reported in patients on anti-PD1 treatments, suggesting the neutrophil as another cell type modulated by anti-PD1 antibodies.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000397DOI Listing

Publication Analysis

Top Keywords

cutaneous adverse
12
anti-programmed cell
12
cell death-1
12
eruption novel
8
novel cutaneous
8
adverse event
8
anti-pd1 therapy
8
patients anti-pd1
8
anti-pd1
5
intracorneal pustular
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!